martes, 27 de febrero de 2007

Documento sobre el uso del PET-TAC y PET-RM

DOCUMENTO SOBRE EL USO DEL PET-TAC Y PET-RM
Debido al carácter interdisciplinario de esta técnica deben establecerse criterios de uso compartido entre las dos especialidades: radiología y medicina nuclear.
En este documento se fija la posición de la SERAM.

http://www.seram.es/docs/documentos/uso_pet-tac_pet-rm.pdf

jueves, 8 de febrero de 2007

PET-CT de 64 cortes en Mexico

Inaugura rector de la UNAM equipo médico único en América Latina

http://www.jornada.unam.mx/ultimas/2007/02/07/inaugura-rector-de-la-unam-equipo-medico-unico-en-america-latina

lunes, 5 de febrero de 2007

PET-CT en portada de Diario Medico

Mi más sincera enhorabuena al grupo del IAT-CRC Corporacion Sanitaria del Hospital del Mar (Barcelona) y en especial al Dr. Trampal

Antonio Maldonado


La colina marcada con carbono 11 es útil en próstata
http://www.diariomedico.com/edicion/diario_medico/mi_dm/oncologia/diagnostico/es/desarrollo/736155_04.html


La PET evita cirugías innecesarias en cáncer pulmonar al estadificarlo mejor
http://www.diariomedico.com/edicion/diario_medico/mi_dm/oncologia/diagnostico/es/desarrollo/736156_05.html

Reunion SMMN Marzo 2007

Ya está disponible en el blog de la SMMN, información sobre nueva reunión científica a celebrar el próximo dia 1 de Marzo
http://soc-mmn.blogspot.com/

Un saludo
Dr. Antonio Maldonado
Sociedad Madrileña de Medicina Nuclear

sábado, 3 de febrero de 2007

Revised Response Criteria for Malignant Lymphoma

Revised Response Criteria for Malignant Lymphoma.
J Clin Oncol. 2007 Jan 22
Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., Coiffier B., Fisher R.I., Hagenbeek A., Zucca E., Rosen S.T., Stroobants S., Lister T.A., Hoppe R.T., Dreyling M., Tobinai K., Vose J.M., Connors J.M., Federico M., Diehl V.

Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC; University of Cologne, Cologne; Department of Nuclear Medicine, University of Iowa, Iowa City, IA; Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Department of Oncology and Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark; Division of Oncology and Department of Radiation Oncology, Stanford University, Stanford, CA; Department of Hematology, Hospices Civils de Lyon and Universite Claude Bernard, Lyon, France; James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Academic Medical Center, Department of Hematology, Amsterdam, the Netherlands; Lymphoma Unit, Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium; Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Department of Medicine III, University of Munich, Hospital Grosshadern, Munich, Germany; Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan; Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE; and Dipartimento di Oncologia ed Ematologia, Universita di Modena e Reggio Emilia, Modena, Italy.
PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [(18)F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma



Enviado por: Antonio Maldonado (3/2/07)


Captaciones en estomago

Intense F-18 FDG Uptake in the Stomach Wall in Follicular Gastritis in Zollinger-Ellison Syndrome.
Clin Nucl Med. 2007 Feb;32(2):150-1.
Basu S., Nair N.
From the Radiation Medicine Centre, Bhabha Atomic Research Centre, Bombay, India.
A 59-year-old woman, who had surgery for a suspected pancreatic tumor and was detected to have a gastrinoma, was referred for F-18 FDG PET for disease evaluation. Whole-body FDG PET showed diffuse intense FDG PET uptake (SUVmax 5.44) throughout the stomach. The patient was asked to drink a large amount of water and a repeat spot FDG PET (limited to the surface marking of the stomach) was acquired. The uptake was mildly reduced (SUVmax 4.75) but persisted in the distended stomach wall. An endoscopic biopsy from the antrum and fundus revealed follicular gastritis with erosion. The biopsy was negative for neoplasm. The patient was thought to have gastritis in a Zollinger-Ellison syndrome. Varying degrees of FDG uptake in the stomach have been described in certain benign conditions. Gastritis secondary to Zollinger-Ellison syndrome should be included in the differential diagnosis of diffuse intense gastric uptake, when such a history is present in the patient
-----------------------------------------

Gastric Distension by Ingesting Food Is Useful in the Evaluation of Primary Gastric Cancer by FDG PET.
Clin Nucl Med. 2007 Feb;32(2):106-109.
Zhu Z., Li F., Zhuang H.
From the *Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and the daggerDepartment of Radiology, the Children's Hospital of Philadelphia, Philadelphia, PA.
Gastric carcinoma is the second leading cause of cancer-related death worldwide. Detection and surgical resection of gastric cancer in the early stage provides the only hope for improved survival in patients with gastric cancer. Positron emission tomography (PET) with F-18 2-deoxy-2-fluoro-D-glucose (FDG) has been shown to be essential in the evaluation of a variety of malignancies. However, conventional FDG PET has limited value for detecting a primary tumor of the stomach, mostly because of the relatively high levels of physiological uptake by the contracted stomach. We report 3 cases of primary gastric carcinomas detected successfully by FDG PET after the ingestion of food. The PET images of the stomach after ingesting food were compared with the routine fasting-state whole-body PET images for each patient. When the stomach was distended by food, the malignant lesions were more discernible. These cases indicate that gastric distension by ingesting food may be a simple method that can help to detect a primary gastric malignancy by FDG PET.


Enviado por: Antonio Maldonado (3/2/07)

viernes, 2 de febrero de 2007

Conferencia de D. W. Townsend, inventor del PET-CT, en el CIEMAT

Asunto: Conferencia de D. W. Townsend, inventor del PET-CT, en el CIEMAT
Conferencia de D. W. Townsend sobre "The evolution of hybrid imaging: the path of no return", el jueves 15 de febrero de 2007 a las 15:00 en el Auditorio del CIEMAT.
El título de la conferencia es "The evolution of hybrid imaging: a path of no return".
Asistencia libre.

Enviado por: Antonio Maldonado (2/2/07)